L
LePure Biotech
Single-use solutions for the biopharmaceutical industry
About LePure Biotech
LePure Biotech operates in the biopharmaceutical industry, providing innovative bioprocess solutions. The company serves a diverse range of clients, including global biopharma companies, by offering customized integrated bioprocess solutions. LePure Biotech's business model revolves around research and development, manufacturing, and commercial operations, ensuring high-quality products and services. The company generates revenue through the sale of its bioprocess solutions, which include single-use systems and other bioprocessing equipment. LePure Biotech is recognized for its commitment to technology innovation and adherence to international quality standards, making it a reliable partner for its clients. The company has been acknowledged for its investment value in the healthcare sector and has a strong presence in both domestic and international markets. Key achievements include obtaining the US FDA Type III DMF filing number and being recognized as one of the top healthcare enterprises with investment value.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Westborough, United States
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 49.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Aug 2024
- Capital deployed
- $8.6M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jan 2023 | — | — | Goldman Sachs Asset Management · China Science and Technology Innovation · HM Capital · Bayland Capital | ↗ |
| SERIES B✓Equity / VC | Dec 2021 | — | — | Fortune Capital · Shanghai CICC Capital · HM Capital | — |
Growth signals
Latest recorded traffic for LePure Biotech is 0 monthly website visits, down 100% over the last three months. LePure Biotech's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PL BioScienceAachen, GermanyThe platform of tailored cell culture supplements based on human Platelets
$34Mvaluation
S(
Stanley Biotechnology (Hangzhou)China
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- XCXinjin Venture Capital
Legend Capital- FCFortune Capital
Shanghai CICC Capital
HM Capital
Series B and later7 investors entered at this stage
Goldman Sachs Asset Management- CIChina Science and Technology Innovation
Bayland Capital
General Atlantic
Novo Holdings
Highlight Capital- HFHuaying Health Fund
Other known investors7 additional known investors
Goldman Sachs
Hillhouse Capital- HCHonghui Capital
- HFHua Ying Health Fund
Huimei Technology- KCKangjun Capital
New Alliance Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LePure Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LePure Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.